Keros Therapeutics, Inc. (KROS)
KROS Stock Price Chart
Explore Keros Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze KROS price movements and trends.
KROS Company Profile
Discover essential business fundamentals and corporate details for Keros Therapeutics, Inc. (KROS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Apr 2020
Employees
163.00
Website
https://www.kerostx.comCEO
Jasbir S. Seehra
Description
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS Financial Timeline
Browse a chronological timeline of Keros Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$1.25, while revenue estimate is $807.14k.
Earnings released on 14 May 2026
EPS came in at -$1.21 falling short of the estimated -$0.92 by -31.52%, while revenue for the quarter reached $367.00k , missing expectations by -80.97%.
Earnings released on 4 Mar 2026
EPS came in at -$0.86 falling short of the estimated -$0.49 by -75.51%, while revenue for the quarter reached $385.00k , missing expectations by -89.50%.
Earnings released on 5 Nov 2025
EPS came in at -$0.18 surpassing the estimated -$1.11 by +83.78%, while revenue for the quarter reached $14.26m , beating expectations by +289.41%.
Earnings released on 6 Aug 2025
EPS came in at -$0.76 surpassing the estimated -$1.14 by +33.33%, while revenue for the quarter reached $18.17m , beating expectations by +465.88%.
Earnings released on 6 May 2025
EPS came in at $3.62 surpassing the estimated -$0.01 by +36.30k%, while revenue for the quarter reached $211.25m , beating expectations by +272.93%.
Earnings released on 26 Feb 2025
EPS came in at -$1.14 surpassing the estimated -$1.36 by +16.18%, while revenue for the quarter reached $3.04m , missing expectations by -86.32%.
Earnings released on 6 Nov 2024
EPS came in at -$1.41 falling short of the estimated -$1.26 by -11.90%, while revenue for the quarter reached $388.00k , missing expectations by -83.20%.
Earnings released on 7 Aug 2024
EPS came in at -$1.25 falling short of the estimated -$1.23 by -1.63%, while revenue for the quarter reached $37.00k .
Earnings released on 8 May 2024
EPS came in at -$1.21 surpassing the estimated -$1.31 by +7.63%, while revenue for the quarter reached $83.00k .
Earnings released on 28 Feb 2024
EPS came in at -$1.34 surpassing the estimated -$1.38 by +2.90%, while revenue for the quarter reached $143.00k .
Earnings released on 6 Nov 2023
EPS came in at -$1.33 surpassing the estimated -$1.34 by +0.75%, while revenue for the quarter reached $8.00k .
Earnings released on 7 Aug 2023
EPS came in at -$1.27 surpassing the estimated -$1.34 by +5.22%.
Earnings released on 4 May 2023
EPS came in at -$1.26 falling short of the estimated -$1.13 by -11.50%.
Earnings released on 3 Mar 2023
EPS came in at -$1.09 surpassing the estimated -$1.12 by +2.68%.
Earnings released on 3 Nov 2022
EPS came in at -$0.92 surpassing the estimated -$1.26 by +26.98%.
Earnings released on 4 Aug 2022
EPS came in at -$1.13 falling short of the estimated -$1.07 by -5.61%, while revenue for the quarter reached $100.00k .
Earnings released on 5 May 2022
EPS came in at -$1.01 falling short of the estimated -$0.86 by -17.44%.
Earnings released on 9 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$0.94 by +68.09%, while revenue for the quarter reached $20.00m .
Earnings released on 4 Nov 2021
EPS came in at -$0.87 falling short of the estimated -$0.72 by -20.83%.
Earnings released on 5 Aug 2021
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%, while revenue for the quarter reached $100.00k , meeting expectations.
KROS Stock Performance
Access detailed KROS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
